Loading...
Market
What will be the outcome of the Medicare and Medicaid weight-loss drug coverage proposal by end of 2024?
2
Resolution / Starting Odds
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%
Official announcements from the Department of Health and Human Services or the Centers for Medicare & Medicaid Services
Story
Biden Proposes Medicare, Medicaid Cover Wegovy, Mounjaro for 7 Million Americans
Nov 26, 2024, 10:32 AM
President Joe Biden's administration has proposed a new rule that would require Medicare and Medicaid to cover costly weight-loss drugs for millions of Americans with obesity. The proposal aims to expand access to medications such as Novo Nordisk's ($NVO) Wegovy and Ozempic, and Eli Lilly's ($LLY) Mounjaro and Zepbound, potentially making these treatments accessible to over 7 million people, including approximately 3.4 million Medicare recipients and 4 million Medicaid adults. By recognizing obesity as a disease that can be treated with these drugs, the rule would represent a significant shift in healthcare policy. Currently, Medicare pays for limited use of weight-loss drugs. The proposal would need to be finalized by the new administration.
View original story
Similar markets
Cost concerns • 25%
Public health benefits • 25%
Lobbying influence • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 5 million • 25%
5 to 7 million • 25%
7 to 9 million • 25%
More than 9 million • 25%
Yes • 50%
No • 50%
Less than $20 billion • 25%
$20 billion to $35 billion • 25%
More than $35 billion • 25%
No significant impact • 25%
Yes • 50%
No • 50%
Eli Lilly • 33%
Novo Nordisk • 33%
Both equally • 34%
Less than $30 billion • 25%
$30 billion to $35 billion • 25%
$35 billion to $40 billion • 25%
More than $40 billion • 25%